PharmaVoice 100: Page 3

  • A portrait of Dr. Ian Walters framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Ian Walters
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Dr. Ian Walters

    How the CEO of Portage Biotech is steering cancer R&D in a new direction by advancing diverse drug platforms.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Matt Walz framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Matt Walz
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Matt Walz

    The innovative CEO is driving global clinical trial enrollment with a novel approach for the industry.   

    By • Sept. 6, 2022
  • A portrait of Sastry Chilukuri framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Sastry Chilukuri
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Sastry Chilukuri

    The co-CEO of Medidata is ushering in the next generation of clinical trial advancements, making research easier and more patient-focused than ever before.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Giacomo Chiesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Giacomo Chiesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Giacomo Chiesi

    For the head of Chiesi Global Rare Diseases, patient centricity is in his DNA.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Jonathan Steckbeck framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jonathan Steckbeck
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Jonathan Steckbeck

    The CEO, founder and president of Peptilogics is changing the game for the peptide medicine space with a promising pipeline and a disruptive discovery platform.

    By • Sept. 6, 2022
  • A portrait of Bobak Azamian framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Bobak Azamian
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dr. Bobak Azamian

    The CEO is bringing his vision for innovative eye therapies to Tarsus Pharmaceuticals.

    By • Sept. 6, 2022
  • A portrait of Raymond Stevens framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Raymond Stevens
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Raymond Stevens

    The longtime pioneer in new drug discovery methods and founder of Structure Therapeutics has leveraged innovative science for commercial success.

    By • Sept. 6, 2022
  • A portrait of Ann Barnes framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Ann Barnes
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Ann Barnes

    The CEO of Intelligent Medical Objects is growing her company’s diversity initiatives — and its bottom line.

    By PharmaVoice staff • Sept. 6, 2022
  • An illustration of stacked glowing silhouettes.
    Image attribution tooltip

    Illustration: Matthieu Bourel for Industry Dive

    Image attribution tooltip
    Tracker // PharmaVoice 100

    The 2022 PharmaVoice 100

    From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Jeremy Levin framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jeremy Levin
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Jeremy Levin

    Over his 30-year career, the founder, chairman and CEO of Ovid Therapeutics has demonstrated that he is a patient advocate, scientist, clinician and innovator at heart.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Laxmi Bonagiri framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Laxmi Bonagiri
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Laxmi Bonagiri

    EClinical Solutions’ VP of India operations is creating a path to increase the number of women in senior leadership roles while changing the course of diseases for millions.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Pam Diamond framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Pam Diamond
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Dr. Pam Diamond

    The chief medical officer and co-founder of Curavit Clinical Research is bringing a new level of inclusiveness to clinical trials.

    By • Sept. 6, 2022
  • A portrait of Dr. Tania Small framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Tania Small
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Dr. Tania Small

    GSK’s medical oncology head is paving the way for patient-driven drug development and more equitable care.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Jeanne Magram framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jeanne Magram
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Jeanne Magram

    Celsius Therapeutics’ CSO is turning ideas into approved medicines for patients with cancer and autoimmune diseases.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Kuldeep Singh Rajput framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Kuldeep Singh Rajput
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Kuldeep Singh Rajput

    Bringing digital solutions to Big Pharmas adapting to a more patient-centric age, the CEO and founder of Biofourmis has instituted a flexible approach that keeps its tech on the leading edge.

    By • Sept. 6, 2022
  • A portrait of Dawn Berry framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dawn Berry
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dawn Barry

    The co-founder and president of LunaPBC is seeking to eliminate the middlemen in drug development by connecting patients — and their real-world data — directly with researchers.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Otis Johnson framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Otis Johnson
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Otis Johnson

    Clario’s chief diversity, inclusion and sustainability officer is looking to improve clinical trial recruitment with a bottom-up approach that first focuses on internal hiring practices. 

    By • Sept. 6, 2022
  • A portrait of Abigail Jenkins framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Abigail Jenkins
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Abigail Jenkins

    With the belief that empathy is critical to leadership, the former chief commercial and business officer of Lyndra Therapeutics has a strong track record of building teams and accelerating progress.

    By • Sept. 6, 2022
  • A portrait of Mike Gladstone framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Mike Gladstone
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Mike Gladstone

    The global president of Pfizer's Inflammation and Immunology unit is unlocking his team’s potential to meet big goals against a promising pipeline.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Sebastian Guth framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Sebastian Guth
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Sebastian Guth

    Bayer Pharmaceuticals’ president, Americas Region, is driving equality efforts both within the company and for patients.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Helen Thackray framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Helen Thackray
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Helen Thackray

    The chief research and development officer at BioCryst Pharmaceuticals is leaning into decades of experience to advance a promising pipeline of rare disease products.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Julie Kim framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Julie Kim
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Julie Kim

    The president of Takeda’s U.S. business unit and U.S. country head has steered through the pandemic, turning her aptitude for bringing people together into a master class in perseverance.

    By • Sept. 6, 2022
  • A portrait of Carol Lynch framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Carol Lynch
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Carol Lynch

    The chief business officer for Sandoz combines a shrewd business sense with a generous approach to leadership.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Lori Abrams framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Lori Abrams
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Lori Abrams

    The VP of patient advocacy and clinical research diversity at WCG is shaking up the trial space by shining a light on underserved populations.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Edward Kaye framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Edward Kaye
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Edward Kaye

    The CEO behind the first genetic therapy for Duchenne muscular dystrophy is looking to extend his winning streak at Stoke.

    By PharmaVoice staff • Sept. 6, 2022